Compositions and methods for treatment of individuals diagnosed with a
dystrophin deficiency are disclosed. In particular, inhibitors of
NF.kappa.B activation, such as pyrrolidine dithiocarbamate (PDTC), have
been shown to prevent and reverse muscle damage in animals lacking
dystrophin. Such compositions and methods are useful in the treatment of
individuals with muscular dystrophy.